Harbour Capital Advisors’s Krystal Biotech KRYS Stock Holding History

Harbour Capital Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$281K	Buy	+845	New	+$293K	0.05%	257

Other funds holding KRYS

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return

TNAM

Terra Nova Asset Management New York $155M AUM 33.52% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Harbour Capital Advisors's KRYS Position: Q3 2026 in Review

Harbour Capital Advisors opened a new position in Krystal Biotech (KRYS) in Q3 2026: 845 shares worth $281K. The stake represents 0.05% of the portfolio and ranks #257 among its holdings.

22 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

Harbour Capital Advisors held 845 shares of Krystal Biotech worth $281K as of Q3 2026.
Krystal Biotech was a new Harbour Capital Advisors position in Q3 2026.
Krystal Biotech made up 0.05% of Harbour Capital Advisors's portfolio in Q3 2026, its #257 holding.
22 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Harbour Capital Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.